Rituximab and Gemcitabine for Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Status:
Terminated
Trial end date:
2007-03-01
Target enrollment:
Participant gender:
Summary
Rituximab has been demonstrated to sensitize drug-resistant NHL cells to the cytotoxic
actions of several chemotherapy agents by enhancing sensitivity of tumor cells to
chemotherapy-induced apoptosis. Gemcitabine, a nucleoside analog that is used in several
other malignancies, has shown very promising activity in patients with refractory Hodgkin's
disease and low-grade NHL. The combination of rituximab and gemcitabine may have synergistic
cytotoxic action in patients with relapsed or refractory DLBCL and possibly lead to improved
response rates and demonstrable clinical benefit.
This trial will investigate the efficacy the combination of rituximab and gemcitabine in
treating patients with relapsed or refractory DLBCL.